PURIFICATION AND RECONSTITUTION OF ACTIVE GAMMA SECRETASE COMPLEX
活性伽玛分泌酶复合物的纯化和重构
基本信息
- 批准号:7483170
- 负责人:
- 金额:$ 42.79万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-09-01 至 2008-08-31
- 项目状态:已结题
- 来源:
- 关键词:Active SitesAddressAffinityAlzheimer&aposs DiseaseAmyloid beta-ProteinAmyloid beta-Protein PrecursorAspartateAspartic EndopeptidasesBindingBiochemicalBiochemical GeneticsBiological AssayBiologyC83Caenorhabditis elegansCalciumCellsChemicalsClassCleaved cellComplexCytoplasmic ProteinDetergentsDevelopmentDiseaseDockingEndopeptidasesEnvironmentEnzymesGeneticGoalsGuanosine TriphosphateHealthIn VitroIntegral Membrane ProteinIonsKineticsKnowledgeLaboratoriesLightMTCH1 geneMammalian CellMass Spectrum AnalysisMediator of activation proteinMembrane ProteinsMetabolicPVRL1Peptide HydrolasesPhospholipidsPropertyProteinsProteolysisProtocols documentationRangeRateResearchSignal PathwayTherapeuticTimeTransmembrane DomainVesicleWorkYeastsbasebeta-site APP cleaving enzyme 1calsenilincofactordesigndimergamma secretasehuman APH-1 proteinhuman PEN-2 proteininhibitor/antagonistinterestmembernicastrin proteinnotch proteinnovelpresenilinreconstitutionscale upsecretasesizestoichiometry
项目摘要
Gamma-Secretase is an unusual enzyme that catalyzes the intramembrane proteolysis of numerous type I integral membrane proteins. These include the amyloid-beta protein precursor (APP), which releases the amyloid-beta peptide (Abeta) implicated in Alzheimer's disease (AD). For this reason, gamma-secretase is a prime target for the development of therapeutic and preventative agents for AD. Pharmacological, genetic, and biochemical evidence generated under this project strongly supports the hypothesis that the polytopic membrane protein, presenilin (PS), is the catalytic component of a larger multi-protein gamma-secretase complex. PS is normally cleaved into two fragments that remain associated. These heterodimers are metabolically stable, and their formation is tightly regulated by limiting cellular factors. During the current project period, we discovered that both PS endoproteolysis and gamma-secretase
activity require two conserved transmembrane aspartates, consistent with our provocative hypothesis that presenilin undergoes autoproteolysis to become the catalytic component of a novel aspartyl protease. Moreover, using affinity isolation on a designed inhibitor, we showed that the PS-associated protein, nicastrin, is another member of the complex. Recently, our laboratory has found that the co-expression of PS1, nicastrin, and two proteins identified in C. elegans, aph-1 and pen-2, results in increased PS heterodimer formation, full nicastrin
maturation and enhanced gamma-secretase activity. All 4 proteins co-immunoprecipitate and bind to a gamma-secretase affinity matrix. Taken together, these new finding suggest that PS, nicastrin, aph-1, and pen-2 assemble as a complex that leads to the formation of active gamma-secretase. In light of these discoveries, we now propose to purify, fully characterize and then reconstitute active gamma-secretase. Specifically, we will: 1) scale up and refine the multi-step purification protocols for gamma-secretase established by our labs in order to unequivocally confirm the presence of these 4 key components and search for any additional protein factors by mass spectrometry; 2) systematically explore phospholipid, detergent, ionic, energy, pH and other requirements to optimize our established in vitro cleavage assay (which can generate Abeta, AICD and NICD) and characterize the kinetic properties of the protease;
and 3) using this new knowledge, carry out the step-wise addition of recombinantly expressed PS, nicastrin, aph-1, and pen-2 in a pure detergent/phospholipid environment to reconstitute proteolysis. The purification, detailed characterization, and reconstitution of gamma-secretase will aid the understanding of this essential protease in health and disease and the search for effective and safe AD therapeutics. Moreover, this work will advance our fundamental knowledge of a unique new class of intramembrane-cleaving proteases.
γ -分泌酶是一种罕见的酶,催化许多I型整体膜蛋白的膜内蛋白水解。这些包括淀粉样蛋白前体(APP),它释放与阿尔茨海默病(AD)有关的淀粉样蛋白肽(Abeta)。因此,分泌酶是开发AD治疗和预防药物的主要目标。该项目产生的药理学、遗传学和生化证据有力地支持了多聚膜蛋白早老素(PS)是一个更大的多蛋白γ -分泌酶复合物的催化成分的假设。PS通常被分裂成两个相互关联的片段。这些异源二聚体在代谢上是稳定的,它们的形成受到限制性细胞因子的严格调控。在目前的项目期间,我们发现了PS内蛋白水解和γ -分泌酶
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DENNIS J SELKOE其他文献
DENNIS J SELKOE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DENNIS J SELKOE', 18)}}的其他基金
A new look at mechanism-based Alzheimer's Disease biomarkers in blood
对血液中基于机制的阿尔茨海默病生物标志物的新认识
- 批准号:
9763401 - 财政年份:2018
- 资助金额:
$ 42.79万 - 项目类别:
Pathological Changes of Alpha-Synuclein Structure in the Brain
大脑α-突触核蛋白结构的病理变化
- 批准号:
9788107 - 财政年份:2018
- 资助金额:
$ 42.79万 - 项目类别:
Biology of Native Alpha-Synuclein Tetramers in Parkinson's Disease
天然 α-突触核蛋白四聚体在帕金森病中的生物学
- 批准号:
8631204 - 财政年份:2014
- 资助金额:
$ 42.79万 - 项目类别:
Pathogenic Mechanisms of Cell-Derived Abeta Oligomers
细胞源性 Abeta 寡聚物的致病机制
- 批准号:
8337011 - 财政年份:2011
- 资助金额:
$ 42.79万 - 项目类别:
AMYLOID B-PROTEIN AND IMMUNE MARKERS IN HUMAN BLOOD
人类血液中的 B 淀粉样蛋白和免疫标记物
- 批准号:
7719366 - 财政年份:2008
- 资助金额:
$ 42.79万 - 项目类别:
AMYLOID B-PROTEIN AND IMMUNE MARKERS IN HUMAN BLOOD
人类血液中的 B 淀粉样蛋白和免疫标记物
- 批准号:
7607424 - 财政年份:2007
- 资助金额:
$ 42.79万 - 项目类别:
Alpha-Synuclein, PUFA and Membrane Vesicles-Health/PD
α-突触核蛋白、PUFA 和膜囊泡-健康/PD
- 批准号:
7032775 - 财政年份:2006
- 资助金额:
$ 42.79万 - 项目类别:
Pathogenic Mechanisms of Cell-Derived Abeta Oligomers
细胞源性 Abeta 寡聚物的致病机制
- 批准号:
7027342 - 财政年份:2006
- 资助金额:
$ 42.79万 - 项目类别:
Pathogenic Mechanisms of Cell-Derived Abeta Oligomers
细胞源性 Abeta 寡聚物的致病机制
- 批准号:
7798985 - 财政年份:2006
- 资助金额:
$ 42.79万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 42.79万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 42.79万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 42.79万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 42.79万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 42.79万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 42.79万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 42.79万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 42.79万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 42.79万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 42.79万 - 项目类别:
Research Grant














{{item.name}}会员




